About KEYMED BIO-B Company

Conoya Biopharmaceutical Technology Co., Ltd. is a biotechnology company with multiple clinical-stage assets, each of which is a strong contender in its respective competitive field. We are focused on the independent discovery and development of innovative biologic therapies to address substantial unmet medical needs in the autoimmune and oncology spaces. Leveraging a robust foundation in biomedical research, we have mastered proprietary drug discovery and development capabilities, including the technologies underpinning our innovative antibody discovery platform and our proprietary novel T-cell redirecting (nTCE) bispecific antibody platform. In less than five years since our founding, we have consistently pursued highly challenging therapeutic areas where demand outstrips supply. Today, we have over ten drug candidates in internal R&D, five of which have advanced into clinical stages. Our pipeline-in-development incorporates cutting-edge scientific breakthroughs, reflecting our deep market insights. Driven by economic growth and healthcare system reforms, healthcare spending has grown significantly over the first two decades of the new millennium. With rapid urbanization, shifting lifestyles, and environmental changes, China's epidemiological landscape is transitioning from infectious disease prevalence to higher rates of cancer and other chronic conditions. These fundamental and evolving trends present new public health challenges and highlight emerging disease areas that impose a heavy societal burden due to inadequate treatment options. To support our innovative biologics R&D efforts, we have established a comprehensive, integrated platform that encompasses all key functions of biologics development, including target validation, lead compound generation and optimization, preclinical evaluation, process development, translational research, clinical development, and manufacturing. This integrated platform enables us to rapidly and cost-effectively discover, build, expand, and advance a diversified pipeline of innovative, differentiated antibody therapies—ranging from monoclonal antibodies and antibody–drug conjugates to bispecific antibodies.